Stoke Therapeutics

Stoke Therapeutics company information, Employees & Contact Information

Explore related pages

Stoke Therapeutics email format Stoke Therapeutics management contacts

Related company profiles:

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.

Company Details

Employees
154
Founded
-
Address
45 Wiggins Ave, Bedford,massachusetts 01730,united States
Phone
781-430-8200
Email
in****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
stoketherapeutics.com
Keywords
Representative jobs.
HQ
Bedford, Massachusetts
Competitors
Sarepta Therapeutics, Dyne Therapeutics, Beam Therapeutics, Praxis Precision Medicines, Inc., Vertex Pharmaceuticals, Biogen, Verve Therapeutics, Avidity Biosciences, Inc., Alnylam Pharmaceuticals, Entrada Therapeutics.
Looking for a particular Stoke Therapeutics employee's phone or email?

Stoke Therapeutics Questions

News

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress - Biogen

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress Biogen

Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA) - Business Wire

Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA) Business Wire

Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer - Business Wire

Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer Business Wire

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments - Biogen

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments Biogen

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates Yahoo Finance

Biogen and Stoke Therapeutics Announce First Patient Dosed - GlobeNewswire

Biogen and Stoke Therapeutics Announce First Patient Dosed GlobeNewswire

Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025 - Business Wire

Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025 Business Wire

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates - Business Wire

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates Business Wire

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome - Biogen

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome Biogen

Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire

Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates Business Wire

Stoke Therapeutics Announces CEO Transition - Business Wire

Stoke Therapeutics Announces CEO Transition Business Wire

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome - Business Wire

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome Business Wire

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress - Business Wire

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress Business Wire

Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer - Seeking Alpha

Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer Seeking Alpha

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome - Yahoo Finance

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome Yahoo Finance

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting - Yahoo Finance

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting Yahoo Finance

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome - Business Wire

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome Business Wire

Stoke Therapeutics to Present at Upcoming Investor Conferences in September - Stock Titan

Stoke Therapeutics to Present at Upcoming Investor Conferences in September Stock Titan

Stoke Therapeutics Launches Global Phase III Trial of Zorevunersen for Dravet Syndrome. - PharmiWeb.com

Stoke Therapeutics Launches Global Phase III Trial of Zorevunersen for Dravet Syndrome. PharmiWeb.com

Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases - Business Wire

Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases Business Wire

Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company’s Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Protein Expression - Business Wire

Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company’s Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Protein Expression Business Wire

Companies like Stoke Therapeutics

Verve Therapeutics logo - Similar company to Stoke Therapeutics

Verve Therapeutics

309
Dyne Therapeutics logo - Similar company to Stoke Therapeutics

Dyne Therapeutics

227
Vertex Pharmaceuticals logo - Similar company to Stoke Therapeutics

Vertex Pharmaceuticals

6.09K
Beam Therapeutics logo - Similar company to Stoke Therapeutics

Beam Therapeutics

557
Entrada Therapeutics logo - Similar company to Stoke Therapeutics

Entrada Therapeutics

191
Alnylam Pharmaceuticals logo - Similar company to Stoke Therapeutics

Alnylam Pharmaceuticals

2.58K
Biogen logo - Similar company to Stoke Therapeutics

Biogen

7.60K
Sarepta Therapeutics logo - Similar company to Stoke Therapeutics

Sarepta Therapeutics

1.37K
Praxis Precision Medicines, Inc. logo - Similar company to Stoke Therapeutics

Praxis Precision Med...

156
Avidity Biosciences, Inc. logo - Similar company to Stoke Therapeutics

Avidity Biosciences,...

491

Top Stoke Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant